Shopping Cart
- Remove All
Your shopping cart is currently empty
MRE-269 (ACT-333679) is an orally available and long-acting prostacyclin receptor agonist prodrug. MRE-269(ACT-333679) is used for the treatment of pulmonary arterial hypertension. MRE-269(ACT-333679) is an active metabolite of Selexipag (S253150).

| Pack Size | Price | Availability | Quantity |
|---|---|---|---|
| 5 mg | $47 | In Stock | |
| 10 mg | $89 | In Stock | |
| 25 mg | $143 | In Stock | |
| 50 mg | $196 | In Stock | |
| 100 mg | $330 | In Stock | |
| 1 mL x 10 mM (in DMSO) | $52 | In Stock |
| Description | MRE-269 (ACT-333679) is an orally available and long-acting prostacyclin receptor agonist prodrug. MRE-269(ACT-333679) is used for the treatment of pulmonary arterial hypertension. MRE-269(ACT-333679) is an active metabolite of Selexipag (S253150). |
| Targets&IC50 | IP receptor (human):20 nM(Ki) |
| Synonyms | MRE269, MRE 269, ACT-333679 |
| Molecular Weight | 419.52 |
| Formula | C25H29N3O3 |
| Cas No. | 475085-57-5 |
| Smiles | N(CCCCOCC(O)=O)(C(C)C)C=1N=C(C(=NC1)C2=CC=CC=C2)C3=CC=CC=C3 |
| Relative Density. | 1.160 g/cm3 |
| Color | White |
| Appearance | Solid |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 55 mg/mL (131.1 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.